Thereafter, approval of adjuvant therapy for stage III melanoma with anti-PD-1 antibodies, pembrolizumab and nivolumab, regardless of the tumor BRAF mutational status, opened to additional treatment possibilities. This evidence concerns the gene BRAF and neoplasm.